Table 2. Outcomes at 15 months of second-line ART.
| Workplace | Community | |||
| N = 205 (N, %) | N = 212 (N, %) | pa | ||
| Clinical outcomes at 15 months | ||||
| Alive and in care | 151 (73.7) | 179 (84.4) | <0.01 | |
| Diedb | 12 (5.8) | 12 (5.7) | - | |
| Lost to follow-up | 29 (14.0) | 15 (7.1) | - | |
| Transfer out | - | 5 (2.4) | - | |
| Other e.g. left employment | 13 (6.3) | 1 (0.5) | - | |
| Non-adherence reported on second-line ART | 37 (17.9) | 3 (1.4) | <0.01 | |
| Change in CD4 count from switch to 12m following switch, range 9-15m (mean, 95% CI), N = 127/162 | +68 (40-95) | +127 (101-154) | <0.01 | |
| VL<400 within 15m of regimen start, range 2wks-15m, c N = 203/211 | 98 (48.3) | 152 (72.0) | <0.01 | |
| Viral rebound (≥400) following initial viral suppression, d N = 73/129 | 26 (35.6) | 17 (13.2) | <0.01 | |
a
Chi2 was used for comparison of proportions; paired t-test was used for comparison of mean CD4 count increase;
b
cause of death was available for 19/24 patients: 12 "natural causes" not further specified, 3 pneumonia, 1 tuberculosis, 1 cryptococcal meningitis, 1 gastroenteritis, 1 cerebro-vascular accident;
c
Patients with missing outcome who transferred out of programme or left employment for reasons other than ill-health were excluded from the analysis (N = 2 workplace, N = 1 community). All other patients with missing outcome were treated as failures (N = 11 workplace, N = 12 community);
d
Patients with ≥1 VL measurement following initial viral suppression (VL<400) on second-line ART.